Andrew J. Schwab - 03 Dec 2021 Form 4 Insider Report for Pear Therapeutics, Inc.

Reporting relationship: Director, 10%+ Owner
Issuer ticker: N/A
Reported as of: 03 Dec 2021
Net transaction value: +$2,000,000
SEC form: 4
Accepted by SEC: 07 Dec 2021, 16:25:21 UTC
Next SEC filing: 27 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Stacie S. Aarestad, Attorney-in-Fact

Key filing fact

Andrew J. Schwab filed Form 4 for Pear Therapeutics, Inc. on 07 Dec 2021.

Key facts

This page summarizes Andrew J. Schwab's Form 4 filing for Pear Therapeutics, Inc..
4 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 07 Dec 2021, 16:25.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$2,000,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PEARQ transaction

Class A Common Stock

Award

Transaction value
Shares: +610,361
Change %
Price
Shares after: 610,361
Date: 03 Dec 2021
Ownership: by 5AM Co-Investors IV, L.P.
Footnotes: F1, F4

PEARQ transaction

Class A Common Stock

Award

Transaction value
Shares: +3,172,769
Change %
Price
Shares after: 3,172,769
Date: 03 Dec 2021
Ownership: by 5AM Opportunities I, L.P.
Footnotes: F2, F4

PEARQ transaction

Class A Common Stock

Award

Transaction value
Shares: +14,648,641
Change %
Price
Shares after: 14,648,641
Date: 03 Dec 2021
Ownership: by 5AM Ventures IV, L.P.
Footnotes: F3, F4

PEARQ transaction

Class A Common Stock

Award

Transaction value: $2,000,000
Shares: +200,000
Change %: +6.3%
Price: $10.00^*
Shares after: 3,372,769
Date: 03 Dec 2021
Ownership: by 5AM Opportunities I, L.P.
Footnotes: F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of June 21, 2021, by and among Thimble Point Acquisition Corp., Oz Merger Sub, Inc. and Pear Therapeutics (US), Inc. (f/k/a Pear Therapeutics, Inc.) ("Private Pear"), in exchange for 414,531 shares of preferred stock of Private Pear previously held by 5AM Co-Investors IV, L.P.

Footnote F2

Received in accordance with the terms of the Business Combination Agreement in exchange for 2,154,809 shares of preferred stock of Private Pear previously held by 5AM Opportunities I, L.P.

Footnote F3

Received in accordance with the terms of the Business Combination Agreement in exchange for 9,948,728 shares of preferred stock of Private Pear previously held by 5AM Ventures IV, L.P.

Footnote F4

The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, with respect to these shares, except to the extent of his pecuniary interest therein.

Footnote F5

On June 21, 2021, Issuer entered into subscription agreements with certain investors (the "PIPE Investors") pursuant to which the PIPE Investors agreed to purchase shares of Issuer common stock for $10.00 per share in connection with, and conditioned upon, the substantially concurrent consummation of certain transactions, including the Business Combination. As one of the PIPE Investors, on December 3, 2021, 5AM Opportunities I, L.P. acquired 200,000 shares of Issuer common stock for $10.00 per share.